Press Releases

Webcast
8th Annual SVB Leerink Global Healthcare Conference
02/27/19 at 2:30 PM EST

Date	Title and Summary
Toggle Summary 02/20/19	AVEO Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 20, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.m.
Toggle Summary 02/16/19	AVEO Oncology Announces Oral Presentation of TIVO-3 Trial Topline Results at the 2019 ASCO Genitourinary Cancers Symposium CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 16, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO -3 study of tivozanib (FOTIVDA ® ) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC).
Toggle Summary 01/31/19	AVEO Oncology Announces NDA Timing Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has accepted the recommendation of the U.S. Food and Drug Administration ( FDA ) not to submit a New Drug Application (NDA) for tivozanib (FOTIVDA®) with the preliminary overall survival (OS)
Toggle Summary 01/02/19	AVEO Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 4:00 p.m. Pacific Time .
Toggle Summary 01/02/19	AVEO Oncology to Present TIVO-3 Data at the 2019 ASCO Genitourinary Cancers Symposium CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that data from the Phase 3 TIVO -3 study of tivozanib (FOTIVDA ® ) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019
Toggle Summary 12/12/18	AVEO Oncology Announces Immuno-Oncology Clinical Collaboration with AstraZeneca Phase 1/2 Study will Evaluate Combination of IMFINZI ® (durvalumab) and FOTIVDA ® (tivozanib) in First-Line HCC CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 12, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has entered into a clinical collaboration with AstraZeneca to evaluate the safety
Toggle Summary 12/04/18	AVEO Oncology Announces Extension of Debt Facility Interest Only Period Extends Cash Runway to Fund Planned Operations into the Third Quarter of 2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced a six-month extension to the interest only period under its existing amended and restated loan and security agreement with
Toggle Summary 11/20/18	AVEO Oncology to Present at the 30th Annual Piper Jaffray Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time .
Toggle Summary 11/15/18	AVEO Oncology Announces $2M Milestone Payment from EUSA Pharma Related to German Commercialization of FOTIVDA® CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 15, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA ® (tivozanib) as a first line
Toggle Summary 11/09/18	AVEO Reports Third Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2018-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2018 and provided a business update. “The recent announcement of positive topline results from the Phase 3 TIVO -3 study in renal cell carcinoma
Toggle Summary 11/05/18	AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint - First and Only Positive Phase 3 Study in Third- and Fourth-Line RCC - - Primary Endpoint Shows 44% Improvement in Median PFS and 26% Reduction in Risk of Progression or Death (HR=0.74, p=0.02) for Tivozanib Compared to Sorafenib - - Data for Secondary Endpoint of Overall Survival Not Yet Mature;
Toggle Summary 10/22/18	AVEO Oncology and EUSA Pharma Announce Updated Interim Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma Tivozanib-Nivolumab Combination Continues to Demonstrate Favorable Efficacy and Safety Data Presented at the European Society of Medical Oncology ( ESMO ) 2018 Annual Congress CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England --(BUSINESS WIRE)--Oct. 22, 2018-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma
Toggle Summary 10/09/18	AVEO Oncology to Present Updated Interim Results from the Phase 2 Portion of the TiNivo Study of Tivozanib and Nivolumab (OPDIVO®) in RCC at the ESMO 2018 Annual Congress CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 9, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO ® ) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology
Toggle Summary 10/01/18	AVEO Oncology Announces Initiation of Topline Analysis of Phase 3 TIVO-3 Trial - Analysis Initiated on the Unanimous Recommendation of the TIVO -3 Study Independent Steering Committee - - Company Expects to Report Topline Results in Approximately 6 Weeks - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has initiated
Toggle Summary 09/25/18	AVEO Oncology to Participate in Upcoming Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2018-- AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the following investor conferences: 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018 at 4:00
Toggle Summary 08/28/18	AVEO Oncology to Participate in Upcoming Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 28, 2018-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO ) today announced that Michael Bailey , president and chief executive officer, will participate in the following investor conferences: B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at
Toggle Summary 08/17/18	AVEO Announces Pricing of $5.7 Million Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 17, 2018-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO ) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.26 per share, the closing price as of yesterday, August 16, 2018 ,
Toggle Summary 08/16/18	AVEO Announces Proposed Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 16, 2018-- AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or
Toggle Summary 08/14/18	AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China - IND acceptance triggers $2M milestone payment from CANbridge to AVEO - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 14, 2018-- AVEO Oncology (Nasdaq: AVEO ) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND)
Toggle Summary 08/07/18	AVEO Reports Second Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2018-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2018 and provided a business update. “Our U.S. registration strategy remains a key focus for AVEO , with topline readout of the Phase 3 TIVO -3 study
Toggle Summary 08/01/18	AVEO Oncology to Present at the Canaccord Genuity 38th Annual Growth Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time .
Toggle Summary 07/19/18	AVEO Oncology Issues Statement Regarding Revised TIVO-3 Trial Guidance CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 19, 2018-- AVEO Oncology (NASDAQ: AVEO ) today issued the following statement regarding its recently revised guidance on the timing of topline data from the TIVO -3 study, its Phase 3 trial of tivozanib as a third-line treatment for advanced renal cell
Toggle Summary 06/25/18	AVEO Oncology Added to the Russell 2000, Russell 3000, and Russell Microcap Indexes CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has been added to the Russell 2000 ® , Russell 3000 ® , and Russell Microcap ® Indexes, effective after the U.S. market closed on Friday, June 22, 2018 as part of FTSE’s annual reconstitution.
Toggle Summary 05/31/18	AVEO Oncology to Present at the Jefferies 2018 Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 31, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will present at the Jefferies 2018 Healthcare Conference in New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time .
Toggle Summary 05/08/18	AVEO Reports First Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2018-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2018 and provided a business update. “We continue to work toward reporting topline results from our Phase 3 TIVO -3 Study, which we now anticipate
Toggle Summary 03/26/18	AVEO Oncology to Present at Upcoming Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the following investor conferences: Needham & Company’s 17th Annual Healthcare Conference on Wednesday, March 28, 2018 at 8:00
Toggle Summary 03/21/18	AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC Results Published in the European Journal of Cancer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 21, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib (FOTIVDA ® ) as second-line treatment in
Toggle Summary 03/13/18	AVEO Reports Full Year 2017 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2018-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2017 and provided a business update. “Last year was one of major progress for AVEO , with highlights including the first commercial launch of
Toggle Summary 03/06/18	AVEO Oncology to Present at the Cowen and Company 38th Annual Health Care Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will present at the Cowen and Company 38 th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:40 a.m. Eastern Time .
Toggle Summary 02/12/18	AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA® (tivozanib) as First Line Treatment for Advanced Renal Cell Carcinoma Recommendation Triggers $2M Milestone Payment from EUSA to AVEO CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD)
Toggle Summary 02/10/18	AVEO Oncology and EUSA Pharma Announce Encouraging Preliminary Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma Data Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England --(BUSINESS WIRE)--Feb. 10, 2018-- AVEO Oncology (NASDAQ: AVEO ) and EUSA Pharma today announced the presentation of preliminary results from the
Toggle Summary 02/07/18	AVEO Oncology to Present at Upcoming Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will present at the following investor conferences: LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018
Toggle Summary 02/01/18	AVEO Announces Appointment of John H. Johnson to Board of Directors CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 1, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced the appointment of John H. Johnson to the Company’s Board of Directors. Mr. Johnson brings to AVEO over three decades of experience in the biotechnology and pharmaceuticals industries, having held
Toggle Summary 01/19/18	AVEO Oncology Announces Presentation of Data from Phase 1b/2 Study of Tivozanib in Patients with Advanced Hepatocellular Carcinoma Poster Presentation Delivered at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 19, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA ®
Toggle Summary 01/04/18	AVEO Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 11:30 a.m. Pacific Time .
Toggle Summary 01/02/18	AVEO Oncology Announces Refinanced Debt Facility Provides Approximately $12.1M in Additional Cash Flow Over 2018-19 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that it has completed the refinancing of its existing $20.0 million debt facility with Hercules Capital, Inc.
Toggle Summary 12/07/17	AVEO Oncology Announces Clinical Updates to Tivozanib and Ficlatuzumab Programs - Enrollment complete in Phase 2 portion of Phase 1/2 TiNivo trial; Next data presentation expected at 2018 Genitourinary Cancers Symposium in February 2018 - - Investigator-sponsored studies of ficlatuzumab initiated in HNSCC and Pancreatic Cancer - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec.
Toggle Summary 11/20/17	AVEO Announces Appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced the appointment of Nikhil Mehta , Ph.D., as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017 . In this role, Dr. Mehta will oversee all aspects of regulatory,
Toggle Summary 11/15/17	EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib) HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 15, 2017-- EUSA Pharma and AVEO Oncology (NASDAQ:AVEO) today announced the first commercial launch of FOTIVDA ® (tivozanib) with the initiation of product sales in Germany . In the European Union , Norway and Iceland , tivozanib is
Toggle Summary 11/08/17	AVEO Oncology to Present at Upcoming Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will be presenting at the following investor conferences: Jefferies 2017 London Healthcare Conference on Wednesday, November 15, 2017 at 4:00
Toggle Summary 11/07/17	AVEO Reports Third Quarter 2017 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2017 and provided a business update. “The third quarter was a transformative period for AVEO , with the achievement of significant milestones in
Toggle Summary 11/06/17	AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma Oral Presentation Delivered at the 16 th International Kidney Cancer Symposium CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England --(BUSINESS WIRE)--Nov. 6, 2017-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the
Toggle Summary 10/16/17	AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 16, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held November 3-4, 2017 in Miami .
Toggle Summary 10/05/17	AVEO Oncology Announces Completion of TIVO-3 Study Futility Analysis with No Changes to Study Protocol CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 5, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced the completion of a pre-planned futility analysis of the Phase 3 TIVO -3 trial, the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA ® (tivozanib) to sorafenib in
Toggle Summary 09/20/17	AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in Exercise of Option Triggers $2.0 Million Research and Development Payment to AVEO CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England --(BUSINESS WIRE)--Sep. 20, 2017-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for
Toggle Summary 09/13/17	AVEO Oncology Announces Receipt of Payments from EUSA Pharma and CANbridge CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA ® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma in
Toggle Summary 09/05/17	AVEO Oncology to Present at Upcoming Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will be presenting at the following investor conferences: The 19 th Annual Rodman & Renshaw Global Investment Conference on Tuesday,
Toggle Summary 08/28/17	AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 28, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that the European Commission (EC) has approved FOTIVDA ® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland .
Toggle Summary 08/09/17	AVEO Reports Second Quarter 2017 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 9, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2017 , and provided a business update. “The second quarter was marked by validating events in each of the three pillars of our global tivozanib
Toggle Summary 06/27/17	AVEO Oncology Announces $14M in Aggregate Gross Proceeds from Hercules Credit Facility and At-the-market Stock Offerings Additional Resources Sufficient to Fund Planned Operations into the 4Q 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 27, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that it has secured $14 million in aggregate gross proceeds through its credit facility with Hercules Capital, Inc.
Toggle Summary 06/23/17	AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for approval as a treatment for
Toggle Summary 06/20/17	AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches Enrollment Target – Pre-planned futility analysis of the trial expected midyear 2017; topline data expected in the first quarter of 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 20, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that the Company’s pivotal TIVO -3 trial, a randomized, controlled,
Toggle Summary 06/08/17	AVEO Oncology Announces Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in RCC Advances to Phase 2 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 8, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that its Phase 1/2 AVEO -sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo ® (nivolumab), in subjects with advanced renal cell carcinoma
Toggle Summary 06/05/17	AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017 AVEO Announces Trial in Progress Poster Also Presented Highlighting Phase 3 TIVO -3 Study of Tivozanib in RCC CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.
Toggle Summary 05/19/17	AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 19, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency
Toggle Summary 05/16/17	AVEO Announces Appointment of Matthew Dallas as Chief Financial Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 16, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017 . In this role, Mr. Dallas will be responsible for the Company’s financial strategy and management as it takes steps
Toggle Summary 05/15/17	AVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2017-- The Board of Directors of AVEO Oncology (NASDAQ:AVEO) today issued the following statement regarding the passing of its Lead Director Henri A. Termeer . “We are deeply saddened at the loss of a visionary, mentor, colleague and dear friend, Henri A.
Toggle Summary 05/08/17	AVEO Oncology Announces Receipt of USPTO Notice of Allowance Related to AV-353 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/653,684, entitled "notch binding agents and antagonists and methods
Toggle Summary 05/04/17	AVEO Reports First Quarter 2017 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017 , and provided a business update. “We strengthened our balance sheet in the first quarter through an underwritten public offering, giving us the
Toggle Summary 04/20/17	AVEO Announces Presentations at the 2017 ASCO Annual Meeting CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology ( ASCO ) Annual Meeting, held June 2-6, 2017 .
Toggle Summary 04/13/17	AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 13, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Issues (LOI) related to the Marketing Authorization
Toggle Summary 04/03/17	AVEO Announces Milestone Payment from CANbridge for AV-203 Company Provides Updated Financial Guidance CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced receipt of a $500,000 milestone payment from CANbridge Life Sciences Ltd. , a biopharmaceutical company focused on developing western drug candidates in China
Toggle Summary 03/31/17	AVEO Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 31, 2017-- AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock, including the exercise in full by the underwriter of its option to purchase
Toggle Summary 03/28/17	AVEO Announces Pricing of $15.0 Million Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 28, 2017-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.50 per share, before underwriting discounts, which would result in
Toggle Summary 03/28/17	AVEO Announces Proposed Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 28, 2017-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether
Toggle Summary 03/22/17	AVEO Reports Full Year 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2016 and provided a business update. “TIVO-3, our lead clinical program designed to serve as the basis for a potential U.S.
Toggle Summary 03/22/17	AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCC CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Phase 1/2 AVEO -sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced
Toggle Summary 02/23/17	AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 23, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO -3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC), has
Toggle Summary 02/09/17	AVEO Announces Clinical and Regulatory Updates for Tivozanib - Pivotal TIVO-3 Trial Enrollment Proceeding Substantially Ahead of Schedule; Enrollment Completion Expected in June - - Phase 1/2 TiNivo Trial Sites Scheduled to Open for Enrollment in Early March - - Partner EUSA Pharma Receives Day 180 List of Outstanding Issues from EMA, Oral Explanation
Toggle Summary 02/06/17	AVEO to Present at the 19th Annual BIO CEO & Investor Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 6, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle , M.D., Chief Medical Officer, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13, 2017 at 8:30 AM E.T.
Toggle Summary 11/28/16	AVEO Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Tivozanib in Renal Cell Carcinoma CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 28, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that its development partner, EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has submitted its responses to the European Medicines Agency (EMA) Day
Toggle Summary 11/22/16	AVEO to Present at the 28th Annual Piper Jaffray Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 22, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 28 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 3:30 PM Eastern Time .
Toggle Summary 11/04/16	AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 4, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2016 . “In the last 18 months, we have made important progress in moving forward both elements of our strategy, including our oncology pipeline,
Toggle Summary 10/12/16	AVEO to Present at the 15th Annual BIO Investor Forum CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 12, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 15th Annual BIO Investor Forum on Wednesday, October 19, 2016 at 11:30 AM Pacific Time .
Toggle Summary 09/30/16	AVEO Oncology Announces Proposed Settlement and Settlement Hearing in 2014 Stockholder Litigation CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 30, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that a settlement hearing will be held on December 19, 2016 at 3:00 p.m. , before the Honorable Denise J. Casper , United States Courthouse , Courtroom No. 11 of the John Joseph Moakley U.S.
Toggle Summary 09/06/16	AVEO to Present at the 18th Annual Rodman & Renshaw Global Investment Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 18 th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 12:30 PM Eastern Time .
Toggle Summary 08/15/16	AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma - Phase 1/2 TiNivo Trial to Commence at the Institut Gustave Roussy in Paris - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO’s oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine
Toggle Summary 08/04/16	AVEO Oncology Reports Second Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2016 . “The second quarter of 2016 marked a defining moment for AVEO , with the initiation of TIVO -3, our Phase 3 pivotal study of tivozanib in
Toggle Summary 06/15/16	AVEO to Present at the 2016 JMP Securities Life Science Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle , M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 11:00 AM Eastern Time .
Toggle Summary 05/26/16	AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 26, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company’s pivotal TIVO -3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory
Toggle Summary 05/18/16	AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell Cancer Private Placement Provides Gross Proceeds of Approximately $17 Million ; Amended Term Loan to Provide up to $10 Million in Funding CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 18, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of
Toggle Summary 05/13/16	AVEO Announces $17 Million Private Placement CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 13, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors.
Toggle Summary 05/10/16	AVEO Oncology Reports First Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 10, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016 . “We achieved several important goals in the first quarter critical to advancing the corporate strategy we outlined early in 2015.
Toggle Summary 05/02/16	AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company’s potent inhibitory antibody
Toggle Summary 03/21/16	AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North America CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Mar. 21, 2016-- AVEO Oncology (NASDAQ:AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia , today announced an exclusive collaboration and license agreement in which
Toggle Summary 03/15/16	AVEO Oncology Reports Full Year 2015 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update. “Over the course of 2015, AVEO has streamlined its organization and taken a fresh strategic direction to create
Toggle Summary 03/09/16	AVEO to Present at the 28th Annual ROTH Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey , president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016 , at 9:00 a.m. Pacific Time .
Toggle Summary 03/01/16	EUSA Pharma and AVEO Announce Submission of Marketing Authorization Application for Tivozanib in Advanced Renal Cell Carcinoma HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 1, 2016-- EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for
Toggle Summary 02/22/16	AVEO Announces Acceptance of Registration Dossier for Tivozanib in RCC by the Ministry of Health of the Russian Federation CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 22, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal cell carcinoma (“RCC”) has been accepted by the Ministry of Health (“MoH”)
Toggle Summary 02/02/16	AVEO to Present at the 18th Annual BIO CEO & Investor Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey , president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 , at 9:00 a.m. Eastern Time .
Toggle Summary 01/06/16	AVEO to Present at Biotech Showcase 2016 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 6, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey , president and chief executive officer, will present at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55 Wyndham in San Francisco .
Toggle Summary 12/21/15	AVEO and EUSA Pharma Announce Exclusive Licensing Agreement for Tivozanib in Europe EUSA to Submit Marketing Authorization Application for Tivozanib in Advanced RCC in Q1 2016 AVEO to Host Conference Call Today, December 21, 2015 at 9:00 AM ET CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England --(BUSINESS WIRE)--Dec. 21, 2015-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma, a
Toggle Summary 11/09/15	AVEO Oncology Reports Third Quarter 2015 Financial Results and Provides Business Update CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2015 and provided a business update. “We completed partnerships for two of AVEO’s lead programs in the third quarter in addition to making
Toggle Summary 11/09/15	AVEO Announces Chairman Tuan Ha-Ngoc Steps Down CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc , after 13 years of service and leadership at AVEO , has stepped down as Chairman and a Director of the Company’s board of directors, effective November 6, 2015 , to pursue interests
Toggle Summary 08/17/15	AVEO Announces Exclusive Worldwide License Agreement for the Development and Commercialization of AV-380 and Related Antibodies CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 17, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor
Toggle Summary 08/10/15	AVEO Oncology Reports Second Quarter 2015 Financial Results Company to Host Midyear Update Conference Call Today, August 10 at 10:00 am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 10, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2015 . “The second quarter was productive on multiple fronts for AVEO
Toggle Summary 08/05/15	AVEO Oncology to Host Midyear Update Conference Call on August 10, 2015 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call on Monday, August 10, 2015 , at 10:00 a.m. Eastern Time to provide an update on recent developments and corporate goals, as well as discuss financial results
Toggle Summary 08/05/15	AVEO Oncology Announces Exclusive Licensing Agreement with Pharmstandard for Tivozanib in Russia, Ukraine and CIS CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group , the largest Russian pharmaceutical group (“Pharmstandard”), for the development, manufacturing and
Toggle Summary 06/30/15	AVEO Oncology Announces Additional Biomarker Analyses from BATON-CRC Tivozanib Study to be Presented at the ESMO 17th World Congress on Gastrointestinal Cancer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 30, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that additional biomarker analyses from the BATON- ( B iomarker A ssessment of T ivozanib in ON cology) CRC study will be presented at the European Society for Medical Oncology (ESMO) 17 th World
Toggle Summary 06/11/15	AVEO Announces FDA Update for Tivozanib in Colorectal Cancer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 11, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC).
Toggle Summary 06/03/15	AVEO Announces Receipt of European Regulatory Guidance Regarding Potential Marketing Authorization Application for Tivozanib CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 3, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for tivozanib in Europe for the treatment of renal cell carcinoma (RCC),
Toggle Summary 05/29/15	AVEO Oncology to Present at Jefferies 2015 Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey , president and chief executive officer, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 8:00 AM (ET) in New York City .
Toggle Summary 05/26/15	AVEO Oncology Announces New Corporate Headquarters in Cambridge, Massachusetts Unveils New Corporate Logo CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 26, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts , effective today. Consistent with the Company’s goal of streamlining operations to
Toggle Summary 05/20/15	AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 20, 2015-- AVEO Oncology (NASDAQ:AVEO) announced today that final results from the TIVO -1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease
Toggle Summary 05/07/15	AVEO Oncology Reports First Quarter 2015 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2015 . “We continue to execute on our strategy of leveraging biomarker insights and exploring partnership opportunities to advance our pipeline, while
Toggle Summary 04/22/15	AVEO Names Keith S. Ehrlich as Chief Financial Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 22, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. Ehrlich will be responsible for the company’s financial and administrative strategy and management, and
Toggle Summary 04/20/15	AVEO Oncology Announces Presentation of AV-380 Preclinical Data in Cancer Associated Cachexia at 2015 Annual Meeting of the American Association of Cancer Research CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor
Toggle Summary 03/06/15	AVEO Oncology Reports Full Year 2014 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2014 . “At the beginning of 2015, AVEO implemented several important changes designed to maximize the value of our portfolio of clinical stage
Toggle Summary 03/06/15	AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib Compared to Bevacizumab in Low Serum NRP-1 Patients with Advanced CRC Results Presented at AACR Tumor Angiogenesis and Vascular Normalization Conference AVEO to Host Conference Call Today, March 6, 2015 at 8:00 am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of final results, including a predefined
Toggle Summary 02/27/15	AVEO Oncology to Host Conference Call to Discuss Presentation of Final Results and Biomarker Analysis from Phase 2 Study of Tivozanib in Patients with Advanced Colorectal Cancer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 27, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call and webcast on Friday, March 6, 2015 , at 8:00 a.m. Eastern Time to discuss the presentation of final results and a predefined biomarker analysis of its
Toggle Summary 01/12/15	AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 12, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey , president and chief executive officer, will present at the 33 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00PM (PT) in San Francisco .
Toggle Summary 01/09/15	AVEO Names Michael N. Needle, M.D., As Chief Medical Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N. Needle , M.D., to the position of Chief Medical Officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating
Toggle Summary 01/08/15	AVEO Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application to the European Medicines Agency Company to Evaluate Potential for Submission of a Tivozanib MAA for the Treatment of RCC CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for
Toggle Summary 01/07/15	AVEO Announces Executive Transition and Corporate Restructuring Michael P. Bailey Named President and Chief Executive Officer; Tuan Ha-Ngoc Named Chairman of the Board Company to Eliminate Internal Research Function to Align Corporate Resources with the Company’s Future Strategic Plans CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan.
Toggle Summary 11/11/14	AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 11, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation , under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small
Toggle Summary 11/05/14	AVEO Oncology Reports Third Quarter 2014 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan. “At AVEO, we continue to execute on all aspects of our strategic plan.
Toggle Summary 09/29/14	AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 29, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for
Toggle Summary 09/29/14	AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat “Poor” Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End MADRID --(BUSINESS WIRE)--Sep. 29, 2014-- AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective
Toggle Summary 09/26/14	AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference MONTREAL --(BUSINESS WIRE)--Sep. 26, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and
Toggle Summary 09/26/14	AVEO Oncology Announces Lease Termination and Amendment to Debt Financing Facility CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 26, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company’s headquarters in Cambridge, Massachusetts ,
Toggle Summary 09/17/14	Clinical Data on AVEO Oncology’s Ficlatuzumab and Tivozanib to Be Presented at the ESMO 2014 Congress CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 17, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company’s hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company’s inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and
Toggle Summary 08/11/14	AVEO Oncology Reports Second Quarter 2014 Financial Results and Updates Progress on Strategic Plan Ficlatuzumab Phase 2 NSCLC Data and Tivozanib Phase 2 CRC and RCC Data to Be Presented at ESMO 2014 Congress AV-380 Preclinical Data to Be Presented at 2nd Cancer Cachexia Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 11, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its second quarter
Toggle Summary 05/31/14	AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical Oncology Annual Meeting CAMBRIDGE, Mass. & CHICAGO --(BUSINESS WIRE)--May 31, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2
Toggle Summary 05/28/14	AVEO Oncology to Present at the Jefferies Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 28, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc , chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2014 at 8:30AM (ET) in New York City .
Toggle Summary 05/07/14	AVEO Oncology Reports First Quarter 2014 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. “We made solid progress executing on a key component of our recently announced corporate
Toggle Summary 05/05/14	AVEO Oncology to Report First Quarter 2014 Financial Results on May 7, 2014 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 5, 2014-- AVEO Oncology (NASDAQ: AVEO ) today announced that the company will release its financial results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014 . Management plans to host financial results conference calls
Toggle Summary 04/10/14	AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC Biodesix to Fund Proof of Concept Study CAMBRIDGE, Mass. & BOULDER, Colo. --(BUSINESS WIRE)--Apr. 10, 2014-- AVEO Oncology (NASDAQ: AVEO ) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF)
Toggle Summary 03/20/14	AVEO Regains Worldwide Rights to AV-203 Agreement with Biogen Idec allows AVEO to seek partner to accelerate clinical development CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 20, 2014-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate,
Toggle Summary 03/13/14	AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan - Company ends 2013 with $118M in cash 1 - - Focuses internal R&D investment on AV-380 in cachexia - - Intends to advance clinical-stage assets through strategic partnering – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2014-- AVEO Oncology (NASDAQ: AVEO ) today reported consolidated 2013
Toggle Summary 03/04/14	AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2014-- AVEO Oncology (NASDAQ: AVEO ) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014 .
Toggle Summary 02/14/14	AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib Phase 2 Colorectal Cancer Study Discontinued AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014 CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Feb. 14, 2014-- AVEO Oncology (NASDAQ: AVEO ) and Astellas Pharma Inc.
Toggle Summary 01/30/14	AVEO and Astellas Discontinue Phase 2 Trial of Tivozanib in Breast Cancer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 30, 2014-- AVEO Oncology (NASDAQ: AVEO ) today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON ( B iomarker A ssessment of T ivozanib in ON cology) breast cancer clinical trial, a Phase 2 study in patients with
Toggle Summary 12/13/13	AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 13, 2013-- AVEO Oncology (NASDAQ: AVEO ) today announced that data from a planned interim analysis of the Phase 2 BATON ( B iomarker A ssessment of T ivozanib in ON cology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely
Toggle Summary 11/07/13	AVEO Reports Third Quarter 2013 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results. “We continue to execute on the strategy we outlined earlier this year, focusing our resources where the unique insights derived from our proprietary Human
Toggle Summary 09/04/13	AVEO Oncology to Present at the Morgan Stanley Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc , chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.m. (ET) in New York City .
Toggle Summary 08/09/13	AVEO Oncology to Present at the Canaccord Genuity 33rd Annual Growth Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 9, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Canaccord Genuity 33 rd Annual Growth Conference on Thursday, August 15, 2013 at 2:00 p.m. (ET) in Boston .
Toggle Summary 08/08/13	AVEO Reports Second Quarter 2013 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported second quarter 2013 financial results. “We are moving forward as an organization and are firmly focused on executing our revised business strategy,” said Tuan Ha-Ngoc , president and chief executive
Toggle Summary 06/10/13	AVEO Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 10, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration ( FDA ) informing the company that the FDA will not approve in its present form the New Drug Application (NDA)
Toggle Summary 06/04/13	AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring that will refocus the company’s efforts and resources on the ongoing clinical development of tivozanib in
Toggle Summary 05/15/13	AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--May. 15, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO -1 trial ( TI vozanib V ersus s O rafenib in 1 st line advanced RCC) of investigational agent tivozanib in
Toggle Summary 05/02/13	AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--May. 2, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s ( FDA ) Oncologic Drugs Advisory Committee (ODAC) voted that the application for investigational agent
Toggle Summary 05/02/13	Trading of AVEO Common Stock Halted FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma AVEO Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 2, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that NASDAQ halted trading of AVEO common stock this morning, May
Toggle Summary 04/29/13	AVEO Reports First Quarter 2013 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported first quarter 2013 financial results. In lieu of a quarterly financial update conference call, the AVEO management team expects to host a conference call on May 2, 2013 following the review by the U.S.
Toggle Summary 03/06/13	AVEO Oncology to Present at the Barclays Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 9:00 a.m. (ET) in Miami .
Toggle Summary 02/27/13	AVEO and Astellas Announce FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma Oncologic Drugs Advisory Committee Meeting Scheduled for May 2, 2013 CAMBRIDGE, Mass. & NORTHBROOK, Ill. --(BUSINESS WIRE)--Feb. 27, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Global Development, Inc. , a U.S. subsidiary of Tokyo -based Astellas Pharma Inc.
Toggle Summary 02/20/13	AVEO Oncology to Present at the 2013 RBC Capital Markets’ Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 20, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Wednesday, February 27, 2013 at 2:00 p.m. (ET) in New York City .
Toggle Summary 02/13/13	AVEO Reports 2012 Financial Results and Highlights Recent Accomplishments CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 13, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2012 financial results and reviewed key recent accomplishments. “We continue to make significant progress with tivozanib, including reporting the final overall survival results from TIVO -1,
Toggle Summary 02/12/13	AVEO and Astellas Report Final Overall Survival Results from TIVO-1 Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Feb. 12, 2013-- AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced overall survival (OS) for tivozanib, an
Toggle Summary 01/31/13	AVEO Oncology Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Conference Call CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2013-- AVEO Oncology (NASDAQ:AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012 will be released before the market opens on Wednesday, February 13, 2013 .
Toggle Summary 01/29/13	AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 ASCO Genitourinary Cancers Symposium CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Jan. 29, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be presented at the 2013
Toggle Summary 01/24/13	AVEO Announces Closing of Public Offering CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 24, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported that it has closed its recently announced public offering of common stock. The total number of shares sold was 7,667,050, comprised of 6,667,000 shares of common stock initially offered and
Toggle Summary 01/22/13	AVEO Announces Exercise of Over-Allotment Option for Recent Public Offering CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 22, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 1,000,050 shares, the full amount of the option granted to the
Toggle Summary 01/17/13	AVEO Prices Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 17, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 6,667,000 shares of its common stock at a price of $7.50 per share to the public. All of the shares are being sold by AVEO.
Toggle Summary 01/16/13	AVEO Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 16, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by AVEO. J.P.
Toggle Summary 12/27/12	AVEO Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 27, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc , president and chief executive officer, is scheduled to present at the 31 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2013 at 11:00 a.m. (PT) in San Francisco .
Toggle Summary 12/20/12	AVEO Oncology Appoints Robert Epstein, M.D., M.S. to its Board of Directors Ronald A. DePinho , M.D. Retires from AVEO Board of Directors CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 20, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Robert Epstein , M.D., M.S. to its Board of Directors, and that Ronald A. DePinho, M.D.
Toggle Summary 12/03/12	AVEO and Astellas Announce Initiation of Patient Enrollment in Phase 2 Trial of Tivozanib in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer BATON-BC Trial Initiation Marks Entry into Third Tumor Type for Tivozanib Clinical Development Program CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Dec. 3, 2012-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a
Toggle Summary 11/28/12	AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Nov. 28, 2012-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for filing the New Drug Application (NDA) for tivozanib with the proposed indication for
Toggle Summary 11/26/12	AVEO Oncology to Present at the Deutsche Bank 2012 dbAccess BioFEST Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 26, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Deutsche Bank 2012 dbAccess BioFEST Conference on Monday, December 3, 2012 at 4:35 p.m. (ET) in Boston .
Toggle Summary 11/06/12	AVEO Oncology to Present at the Lazard Capital Markets 9th Annual Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 6, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 1:00 p.m. (ET) in New York City .
Toggle Summary 10/30/12	AVEO Announces Strategic Restructuring and Provides Third Quarter Financial Results Refocused Resources Projected to Save $100 Million over Three Years Progress Made toward Commercialization of Tivozanib CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 30, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring designed to optimize resources and reduce expenses to
Toggle Summary 10/23/12	AVEO Oncology Announces Timing for Third Quarter Financial Results, Webcast and Conference Call CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 23, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2012 will be released before the market opens on Tuesday, October 30, 2012 . The AVEO management team will host a conference
Toggle Summary 10/01/12	AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer First Patient Enrolled in TAURUS Patient Preference Study Posters 795PD, 796PD and 892TiP CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Oct. 1, 2012-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO -1 trial ( TI vozanib V ersus s O
Toggle Summary 10/01/12	AVEO Announces Detailed Results of Exploratory Phase 2 Study Evaluating Ficlatuzumab in First-Line Patients with Advanced Non-small Cell Lung Cancer; New Data Presented at ESMO Ficlatuzumab Phase 1 Pharmacodynamic Data Also Presented CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company’s HGF inhibitory
Toggle Summary 09/28/12	AVEO and Astellas Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Sep. 28, 2012-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) seeking approval for tivozanib in patients with
Toggle Summary 09/20/12	New Clinical Data on AVEO Oncology’s Tivozanib and Ficlatuzumab to be Presented at the ESMO 2012 Congress CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that new clinical data on its lead product candidate tivozanib, partnered with Astellas Pharma Inc. (TSE: 4503), as well as its HGF inhibitory antibody ficlatuzumab will be presented at the European
Toggle Summary 09/13/12	AVEO Oncology to Present at the UBS Annual Global Life Sciences Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the UBS Annual Global Life Sciences Conference on Thursday, September 20, 2012 at 2:00 p.m. (ET) in New York City .
Toggle Summary 09/03/12	AVEO Oncology to Present at the Morgan Stanley Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Monday, September 10, 2012 at 10:35 a.m. (ET) in New York City .
Toggle Summary 08/09/12	AVEO Oncology to Present at the Canaccord Genuity 32nd Annual Growth Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 9, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Canaccord Genuity 32 nd Annual Growth Conference on Thursday, August 16, 2012 at 10:00 a.m. (ET) in Boston .
Toggle Summary 08/02/12	AVEO Reports Second Quarter 2012 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2012-- AVEO Oncology (NASDAQ: AVEO) today reported consolidated financial results for the second quarter of 2012, and highlighted recent developments and key second quarter accomplishments. “The last six months have been very productive for AVEO Oncology,
Toggle Summary 07/26/12	AVEO Oncology Announces Timing for Second Quarter Financial Results, Webcast and Conference Call CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 26, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's second quarter ended June 30, 2012 will be released before the market opens on Thursday, August 2, 2012 . The AVEO management team will host a conference call
Toggle Summary 06/04/12	AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated in TIVO -1 study CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Jun. 4, 2012-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced plans to initiate a new clinical study, TAURUS ( T ivoz A nib U se ve R s U s S
Toggle Summary 05/30/12	AVEO Oncology to Host Conference Call and Webcast to Review Phase 3 TIVO-1 Data Presented at ASCO CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 30, 2012-- AVEO Oncology (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Monday, June 4, 2012 at 7:30 a.m. (CT) to review the Phase 3 TIVO -1 data that will be presented at the 2012 Annual Meeting of the American
Toggle Summary 05/29/12	AVEO Oncology to Present at the Jefferies 2012 Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 29, 2012-- AVEO Oncology (Nasdaq: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 3:00 p.m. (ET) in New York City .
Toggle Summary 05/23/12	AVEO Initiates Phase 1 Study of AV-203, an ERBB3 Inhibitory Antibody, in Advanced Solid Tumors AV-203 is the Third AVEO Molecule to Enter Clinic CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 23, 2012-- AVEO Oncology (Nasdaq: AVEO) today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced
Toggle Summary 05/16/12	AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year PFS in Patients without Prior Systemic Treatment - - First Pivotal Trial vs. Active Targeted Agent in First-Line Advanced RCC - - Study Results Demonstrate Unique Combination of Superior PFS and Favorable Tolerability - CAMBRIDGE,
Toggle Summary 05/03/12	AVEO Reports First Quarter 2012 Financial Results and Recent Developments CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 3, 2012-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the first quarter of 2012 and reviewed key first quarter accomplishments. “Since the achievement of the primary endpoint in our TIVO -1 study early in the
Toggle Summary 05/02/12	AVEO Announces Preliminary Results of Exploratory Phase 2 Study Evaluating HGF Inhibitor in First-Line Patients with Advanced Lung Cancer Ficlatuzumab/Gefitinib Combination Was Well-Tolerated and Demonstrated Clinical Activity; Study Results Did Not Reach Statistical Significance Encouraging Signals of Anti-tumor Activity in Distinct Subpopulations CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 2, 2012-- AVEO Pharmaceuticals Inc.
Toggle Summary 04/30/12	AVEO Pharmaceuticals, Inc. to Present at Upcoming Investment Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences. Tuan Ha-Ngoc , president and chief executive officer, is scheduled to present at the
Toggle Summary 04/26/12	AVEO Pharmaceuticals, Inc. Announces Timing for First Quarter Financial Results, Webcast and Conference Call CAMBRIDGE, Mass., Apr 26, 2012 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's first quarter ended March 31, 2012 will be released before the market opens on Thursday, May 3, 2012. The AVEO management team will host a conference
Toggle Summary 04/12/12	AVEO Announces Publication of Positive Tivozanib Phase 2 Clinical Trial Results in Journal of Clinical Oncology Tivozanib Demonstrated Improved Median Progression-Free Survival Combined with a Well Tolerated Safety Profile in Patients with Advanced Renal Cell Carcinoma CAMBRIDGE, Mass., Apr 12, 2012 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported results
Toggle Summary 03/27/12	Data on AVEO Pharmaceuticals’ Tivozanib and AV-203 to Be Presented at AACR Annual Meeting 2012 AVEO’s Novel, Internally-Discovered ErbB3 Inhibitory Antibody, AV-203, Entering Clinic This Year CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 27, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed
Toggle Summary 02/27/12	AVEO Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 27, 2012-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc , president and chief executive officer, is scheduled to present at the Cowen and Company 32 nd Annual Health Care Conference on Monday, March 5, 2012 at 4:10 p.m.
Toggle Summary 02/14/12	AVEO Reports 2011 Financial Results and Highlights Fourth Quarter Progress CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today reported consolidated 2011 financial results and reviewed key progress achieved with its tivozanib and ficlatuzumab development programs in the fourth quarter of 2011.
Toggle Summary 02/07/12	AVEO Pharmaceuticals, Inc. Announces Timing for Fourth Quarter and Year-End 2011 Financial Results, Webcast and Conference Call CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2011 will be released before the market opens on Tuesday, February 14, 2012 .
Toggle Summary 02/02/12	AVEO Pharmaceuticals to Present at Several Upcoming Investment Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that members of the company’s management team are scheduled to present a corporate overview at several upcoming investment conferences. The conference and AVEO presentation details are as
Toggle Summary 01/03/12	AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial TIVO -1 is the First Registration Trial to Compare an Investigational Agent to an Approved VEGF Therapy in First-line RCC AVEO Conference Call Today at 8:30 a.m. ET CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Jan. 3, 2012-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Astellas Pharma Inc.
Toggle Summary 01/02/12	AVEO Pharmaceuticals, Inc. Announces Webcast and Conference Call CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Tuesday, January 3, 2012 at 8:30 a.m. (ET) . The call can be accessed by dialing 1-866-825-3354 (domestic) or 1-617-213-8063
Toggle Summary 12/28/11	AVEO Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 28, 2011-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc , president and chief executive officer, is scheduled to present at the 30 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2012 at 11:30 a.m.
Toggle Summary 12/22/11	AVEO Announces Patient Enrollment in Phase 2 Clinical Trial of Tivozanib in Combination with mFOLFOX6 in Patients with Advanced Colorectal Cancer The Trial, BATON-CRC, is Second in Series of Tivozanib Biomarker Trials CAMBRIDGE, MASS .--(BUSINESS WIRE)--Dec. 22, 2011-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called
Toggle Summary 12/01/11	AVEO Pharmaceuticals and Boehringer Ingelheim Announce Manufacturing Agreement for Ficlatuzumab CAMBRIDGE, Mass. & INGELHEIM, Germany --(BUSINESS WIRE)--Dec. 1, 2011-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO’s novel HGF
Toggle Summary 11/03/11	AVEO to Present Tivozanib Clinical Data at Upcoming Oncology Medical Congresses Tivozanib Highlighted at EMUC 2011; New Data Featured at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference CAMBRIDGE, Mass., Nov 03, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported clinical data evaluating its lead product
Toggle Summary 11/02/11	AVEO Pharmaceuticals Reports Third Quarter 2011 Financial Results Company Provides Update on Tivozanib Clinical Program and Timelines CAMBRIDGE, Mass., Nov 02, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.
Toggle Summary 10/26/11	AVEO Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results, Webcast and Conference Call CAMBRIDGE, Mass., Oct 26, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's third quarter ended September 30, 2011 will be released before the market opens on Wednesday, November 2, 2011.
Toggle Summary 08/31/11	AVEO Pharmaceuticals, Inc. to Present at Upcoming Investment Conferences CAMBRIDGE, Mass., Aug 31, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the company's management will present a company overview at upcoming investment conferences. David Johnston, chief financial officer, is scheduled to present at the William Blair 2011
Toggle Summary 08/02/11	AVEO Pharmaceuticals, Inc. to Present at the Canaccord Genuity 31st Annual Growth Conference CAMBRIDGE, Mass., Aug 02, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Canaccord Genuity 31 st Annual Growth Conference on Tuesday, August 9, 2011 at 8:30 a.m.
Toggle Summary 07/28/11	AVEO Reports Second Quarter 2011 Accomplishments and Financial Results CAMBRIDGE, Mass., Jul 28, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reviewed key second quarter accomplishments and reported consolidated financial results for the second quarter of 2011. "We are very pleased with the progress we have made against our corporate goals
Toggle Summary 07/21/11	AVEO Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results, Webcast and Conference Call CAMBRIDGE, Mass., Jul 21, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company's second quarter ended June 30, 2011 will be released before the market opens on Thursday, July 28, 2011.
Toggle Summary 06/21/11	AVEO Pharmaceuticals Announces Closing and Exercise of Over-Allotment Option for Recent Public Offering CAMBRIDGE, Mass., Jun 21, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has closed its previously announced underwritten public offering of common stock. The total number of shares sold was 6,352,119, comprised of 5,750,000 shares of common stock
Toggle Summary 06/15/11	AVEO Pharmaceuticals Prices Public Offering of Common Stock CAMBRIDGE, Mass., Jun 15, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 5,750,000 shares of its common stock at a price of $17.50 per share to the public. All of the shares are being sold by AVEO.
Toggle Summary 06/14/11	AVEO Pharmaceuticals Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass., Jun 14, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by AVEO. J.P.
Toggle Summary 06/02/11	AVEO's Ficlatuzumab in Combination with Gefitinib Well Tolerated in Patients with Non-Small Cell Lung Cancer; Phase 1b Data Presented at ASCO Ongoing Ficlatuzumab Phase 2 Trial Highlighted at ASCO; Patient Enrollment Completed CAMBRIDGE, Mass. & CHICAGO, Jun 02, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in
Toggle Summary 06/02/11	Final Analysis from AVEO Pharmaceuticals' Phase 2 Trial of Tivozanib in Patients with Advanced Renal Cell Carcinoma Presented at ASCO Median PFS Was 11.7 Months among All Treated Patients and 14.8 Months among Those with Clear Cell RCC Who Had Undergone Nephrectomy; Phase 1 Combination Data in RCC and Breast Cancer Also Presented CAMBRIDGE, Mass. & CHICAGO, Jun 02, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc.
Toggle Summary 05/31/11	AVEO Pharmaceuticals Enters into Worldwide License Agreement with Centocor Ortho Biotech to Develop and Commercialize RON-Targeted Antibodies CAMBRIDGE, Mass., May 31, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting
Toggle Summary 05/27/11	AVEO Pharmaceuticals, Inc. to Present at the Jefferies 2011 Global Healthcare Conference CAMBRIDGE, Mass., May 27, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011 at 10:30 a.m.
Toggle Summary 05/18/11	Clinical Data Evaluating AVEO Pharmaceuticals' Tivozanib and Ficlatuzumab to be Presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting CAMBRIDGE, Mass., May 18, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that clinical data evaluating tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and ficlatuzumab (formerly AV-299),
Toggle Summary 04/28/11	AVEO Reports First Quarter 2011 Accomplishments and Financial Results CAMBRIDGE, Mass., Apr 28, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reviewed key first quarter accomplishments and reported consolidated financial results for the first quarter of 2011. "AVEO began 2011 with significant momentum with the commencement of our
Toggle Summary 04/26/11	AVEO Pharmaceuticals, Inc. to Present at the Deutsche Bank Securities 36th Annual Health Care Conference CAMBRIDGE, Mass., Apr 26, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Deutsche Bank Securities 36 th Annual Health Care Conference on Tuesday, May 3, 2011 at 2:50 p.m.
Toggle Summary 04/21/11	AVEO Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results, Webcast and Conference Call CAMBRIDGE, Mass., Apr 21, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company's first quarter ended March 31, 2011 will be released before the market opens on Thursday, April 28, 2011.
Toggle Summary 04/12/11	AVEO Pharmaceuticals Appoints Henri A. Termeer to its Board of Directors CAMBRIDGE, Mass., Apr 12, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the appointment of industry veteran Henri A. Termeer, outgoing chairman, president and chief executive officer of Genzyme Corporation, to its Board of Directors.
Toggle Summary 03/31/11	AVEO Pharmaceuticals, Inc. to Present at the Leerink Swann Cancer Roundtable Conference CAMBRIDGE, Mass., Mar 31, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to participate in a panel titled "Prostate and GU Cancers" at 12:15 p.m.
Toggle Summary 03/28/11	Preclinical Data on AVEO Pharmaceuticals' Tivozanib and Monoclonal Antibody Pipeline to be Presented at AACR 102nd Annual Meeting 2011 CAMBRIDGE, Mass., Mar 28, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that preclinical data on tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company's monoclonal antibody
Toggle Summary 02/23/11	AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences CAMBRIDGE, Mass., Feb 23, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced that members of the company's management team are scheduled to present a corporate overview at several upcoming investment conferences. The conference and AVEO presentation details are as
Toggle Summary 02/16/11	AVEO Reports 2010 Financial Results and Highlights Progress with Tivozanib and Ficlatuzumab CAMBRIDGE, Mass., Feb 16, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated 2010 financial results and reviewed key 2010 accomplishments.
Toggle Summary 02/16/11	Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia -- AVEO to Receive $125 Million Upfront and $1.3 Billion in Potential Milestones -- -- Global 50/50 Profit Share with AVEO to Lead Commercialization in North America and Astellas to Lead Commercialization in Europe -- -- Agreement Accelerates Development of Tivozanib in Multiple Additional Cancer
Toggle Summary 02/14/11	AVEO Pharmaceuticals' Tivozanib Clinical Data Featured at the 2011 ASCO Genitourinary Cancers Symposium CAMBRIDGE, Mass., Feb 14, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in
Toggle Summary 02/10/11	AVEO Pharmaceuticals, Inc. Announces Timing for 2010 Financial Results, Webcast and Conference Call CAMBRIDGE, Mass., Feb 10, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2010 will be released after the market closes on Wednesday, February 16, 2011.
Toggle Summary 02/03/11	AVEO Pharmaceuticals Receives USAN Name for Novel, Internally Discovered Anti-HGF/c-MET Pathway Antibody CAMBRIDGE, Mass., Feb 03, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the
Toggle Summary 02/01/11	AVEO Pharmaceuticals Initiates Enrollment in a Phase 2 Exploratory Biomarker Study of Tivozanib CAMBRIDGE, Mass., Feb 01, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by
Toggle Summary 01/21/11	AVEO Pharmaceuticals' Tivozanib Clinical Data Featured at 2011 ASCO Gastrointestinal Cancers Symposium CAMBRIDGE, Mass., Jan 21, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported positive data from its Phase 1b clinical trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three
Toggle Summary 01/04/11	AVEO Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan 04, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 29 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 10:00 a.m.
Toggle Summary 12/10/10	AVEO's Tivozanib in Combination with Paclitaxel Demonstrates Safety in Patients with Metastatic Breast Cancer; Data Presented at San Antonio Breast Cancer Symposium Data Underscore Potential for Tivozanib to be Safely Combined with Other Anti-Cancer Agents CAMBRIDGE, Mass. & SAN ANTONIO, Dec 10, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer
Toggle Summary 12/02/10	New Clinical Data Evaluating AVEO's Tivozanib in Combination with Paclitaxel to be Presented at 33rd Annual San Antonio Breast Cancer Symposium CAMBRIDGE, Mass., Dec 02, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product
Toggle Summary 12/01/10	OSI Pharmaceuticals, Inc. Exercises Option under Discovery and Translational Research Collaboration with AVEO Option Triggers $25 Million in Milestone Payments to AVEO MELVILLE, N.Y. & TOKYO & CAMBRIDGE, MASS., Dec 01, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc., ("OSI"), which is a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., and
Toggle Summary 11/22/10	AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences CAMBRIDGE, Mass., Nov 22, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company's management will present a company overview at several upcoming
Toggle Summary 11/19/10	AVEO's Anti-RON Monoclonal Antibody Program Highlighted in Late-Breaker Plenary Presentation at EORTC-NCI-AACR Symposium Preclinical Data from the Company's FGFR Antibody Program also Presented CAMBRIDGE, Mass. & BERLIN, Nov 19, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced
Toggle Summary 11/18/10	AVEO's Tivozanib in Combination with FOLFOX6 Demonstrates Anti-tumor Activity and Safety in Advanced GI Cancers; Results Presented at EORTC-NCI-AACR Symposium Preclinical Data Presented Demonstrates that Combining Tivozanib with Chemotherapy Regimens Inhibits Breast Tumor Growth and Prevents Development of Resistance CAMBRIDGE, Mass. & BERLIN, Nov 18, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company
Toggle Summary 11/16/10	AVEO Pharmaceuticals Initiates Patient Enrollment in Phase 1b Tivozanib Combination Trial in Advanced Solid Tumors Trial to Evaluate Tivozanib in Combination with Widely-Used Oral Xeloda ® in Patients with Advanced Breast and Colorectal Cancers CAMBRIDGE, Mass., Nov 16, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and
Toggle Summary 11/10/10	AVEO to Present New Clinical Data Evaluating Tivozanib in Combination with FOLFOX6 at EORTC-NCI-AACR Symposium Tivozanib Data Also Presented at Annual Chemotherapy Foundation Symposium CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new
Toggle Summary 11/04/10	AVEO Reports Third Quarter 2010 Financial Results and Recent Developments Current Financial Position Supports Expanding and Accelerating Clinical Development Plans for Tivozanib CAMBRIDGE, Mass., Nov 04, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer
Toggle Summary 11/03/10	AVEO Pharmaceuticals' Tivozanib Recognized as One of Windhover's 2011 Top 10 Oncology Projects to Watch AVEO to Present at Windhover's Annual Therapeutic Area Partnerships Meeting CAMBRIDGE, Mass., Nov 03, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that its
Toggle Summary 10/29/10	AVEO Pharmaceuticals Announces $61 Million Private Placement Proceeds to Fund Expanding and Accelerating Clinical Development Plans for Tivozanib CAMBRIDGE, Mass., Oct 29, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced
Toggle Summary 10/21/10	AVEO Pharmaceuticals, Inc. Announces Timing for Third Quarter 2010 Financial Results, Webcast and Conference Call CAMBRIDGE, Mass., Oct 21, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company's third quarter ended September 30, 2010 will
Toggle Summary 10/11/10	AVEO Pharmaceuticals' Tivozanib Clinical Data Featured at ESMO CAMBRIDGE, Mass. & MILAN, Oct 11, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib
Toggle Summary 10/01/10	AVEO Pharmaceuticals' Tivozanib Featured at Ninth International Kidney Cancer Symposium Tivozanib Clinical Data and Pipeline Overview Presented CAMBRIDGE, Mass., Oct 01, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported
Toggle Summary 09/30/10	AVEO Pharmaceuticals Regains Worldwide Rights to Develop and Commercialize Anti-HGF Antibody Candidate AV-299 CAMBRIDGE, Mass., Sep 30, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering
Toggle Summary 09/28/10	AVEO Pharmaceuticals, Inc. to Present at Upcoming Oncology Medical Meetings and Investment Conference CAMBRIDGE, Mass., Sep 28, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company will have a presence at two upcoming oncology medical meetings and
Toggle Summary 09/13/10	AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer Company Enhances Leadership Team and Prepares for Forward Integration CAMBRIDGE, Mass., Sep 13, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the appointment
Toggle Summary 09/02/10	AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences CAMBRIDGE, Mass., Sep 02, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company's management will present at several upcoming investment conferences.
Toggle Summary 08/12/10	AVEO Achieves Enrollment Target Ahead of Schedule for Pivotal Phase 3 Trial of Tivozanib in Patients with Advanced Renal Cell Carcinoma CAMBRIDGE, Mass. Aug 12, 2010 -- (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical
Toggle Summary 08/05/10	AVEO Pharmaceuticals, Inc. to Present at the Canaccord Genuity 30th Annual Global Growth Conference CAMBRIDGE, Mass., Aug 05, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at
Toggle Summary 08/02/10	AVEO Pharmaceuticals to Present at Cancer Stem Cells & The Tumor Microenvironment Conference AVEO's Patented Tivozanib Biomarker Highlighted as Part of IBC's Drug Discovery & Development Week CAMBRIDGE, Mass., Aug 02, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics,
Toggle Summary 07/29/10	AVEO Reports Second Quarter 2010 Accomplishments and Financial Results Advancement of Innovative Pipeline; Achievement of Collaboration-Driven Milestone CAMBRIDGE, Mass., Jul 29, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an
Toggle Summary 07/22/10	AVEO Pharmaceuticals, Inc. Announces Timing for Second Quarter 2010 Financial Results, Webcast and Conference Call CAMBRIDGE, Mass., Jul 22, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company's second quarter ended June 30, 2010 will be
Toggle Summary 06/30/10	AVEO Pharmaceuticals' Human Response Platform(TM) and Proprietary Mouse Models Featured in Nature Reviews Cancer CAMBRIDGE, Mass., Jun 30, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the publication of a cover article in the current issue of Nature Reviews Cancer
Toggle Summary 06/29/10	AVEO Pharmaceuticals Added to Russell 2000(R) Index and S&P MidCap 400 CAMBRIDGE, Mass., Jun 29, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company has been added to the Russell 2000(R) Index, as part of the annual
Toggle Summary 06/24/10	AVEO Pharmaceuticals, Inc. Receives Orphan Medicinal Product Designation for Tivozanib for the Treatment of Renal Cell Carcinoma by the European Medicines Agency Designation Reinforces Opportunity for Safe and Effective Treatment Option for Renal Cell Cancer CAMBRIDGE, Mass., Jun 24, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today
Toggle Summary 06/21/10	AVEO Pharmaceuticals to Close NASDAQ Stock Market on June 22, 2010 CAMBRIDGE, Mass., Jun 21, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer of AVEO, will close the NASDAQ
Toggle Summary 06/16/10	AVEO Pharmaceuticals Granted Patents for Diagnostic Tests to Identify Patient Populations Likely to Respond to Tivozanib Treatment AVEO's Human Response Platform(TM) Enables Discovery of Biomarkers to Predict Patient Response CAMBRIDGE, Mass., Jun 16, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today
Toggle Summary 06/07/10	AVEO Pharmaceuticals' Tivozanib Demonstrates Progression-Free Survival of 14.8 Months in Subgroup of Patients with Advanced Kidney Cancer; Extended Duration of Treatment Continues to Highlight Favorable Tolerability Profile Additional Phase 2 Data Presented at ASCO; Phase 3 TIVO-1 Trial Underway to Evaluate Tivozanib's Efficacy and Safety Profile CAMBRIDGE, Mass. & CHICAGO, Jun 07, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and
Toggle Summary 06/05/10	AVEO Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating SCH 900105 (AV-299) in Non-Small Cell Lung Cancer Results of Phase 1 Trial Presented at ASCO Annual Meeting CAMBRIDGE, Mass., Jun 05, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase
Toggle Summary 06/02/10	AVEO Pharmaceuticals to Present at the Bank of America Merrill Lynch 2010 Smid Cap Conference CAMBRIDGE, Mass., Jun 02, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the
Toggle Summary 05/20/10	AVEO Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting Additional Analyses from Phase 2 Trial of Tivozanib and Phase 1 AV-299 Data to be Presented CAMBRIDGE, Mass., May 20, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today
Toggle Summary 04/29/10	AVEO Reports First Quarter 2010 Financial Results Significant Progress in Development of Lead Product Candidate Tivozanib; 2010 Financial Guidance Provided CAMBRIDGE, Mass., Apr 29, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer
Toggle Summary 04/22/10	AVEO Pharmaceuticals, Inc. Announces Timing for First Quarter 2010 Financial Results, Webcast and Conference Call CAMBRIDGE, Mass., Apr 22, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company's first quarter ended March 31, 2010 will be
Toggle Summary 04/21/10	AVEO Pharmaceuticals' Selective Anti-Notch1 Monoclonal Antibody Exhibits Potent Notch1 Inhibitory Activity Data Presented at AACR 101 st Annual Meeting 2010; Confirm Potential Utility of AVEO's Antibody Pipeline CAMBRIDGE, Mass., Apr 21, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer
Toggle Summary 04/14/10	AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody Program Milestone Achieved Through Selection of First ErbB3 Antibody Development Candidate CAMBRIDGE, Mass., Apr 14, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it
Toggle Summary 04/13/10	Data from AVEO Pharmaceuticals' Translational Research Platform and Novel Antibody Pipeline to be Presented at AACR 101st Annual Meeting 2010 CAMBRIDGE, Mass., Apr 13, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline
Toggle Summary 04/01/10	AVEO Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option for Recent Initial Public Offering CAMBRIDGE, Mass., April 1, 2010 --(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO - News), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently completed initial public offering of
Toggle Summary 03/18/10	AVEO Pharmaceuticals, Inc. Completes Initial Public Offering CAMBRIDGE, Mass., Mar 18, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock.
Toggle Summary 03/11/10	AVEO Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering CAMBRIDGE, Mass., Mar 11, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at
Toggle Summary 02/22/10	AVEO Initiates Enrollment in Phase 3 Clinical Trial Evaluating Tivozanib in Advanced Renal Cell Cancer CAMBRIDGE, Mass., February 22, 2010 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has initiated enrollment in a global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor,
Toggle Summary 12/16/09	AVEO Pharmaceuticals Files Registration Statement for Initial Public Offering CAMBRIDGE, Mass., December 16, 2009—AVEO Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock.
Toggle Summary 11/17/09	AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting Preclinical Combination Data Also Presented, Demonstrate mTOR-Tivozanib Combination in Breast Tumor Model Prevents Emergence of Resistance CAMBRIDGE, Mass., November 17, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer
Toggle Summary 09/16/09	AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors CAMBRIDGE, Mass., September 16, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of William J.
Toggle Summary 09/04/09	AVEO Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference CAMBRIDGE, Mass., September 4, 2009 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Rodman & Renshaw 11th Annual Healthcare Conference on Friday, September 11, 2009 at 10:50 a.m.
Toggle Summary 08/04/09	AVEO Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference CAMBRIDGE, Mass., August 4, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Canaccord Adams 29th Annual Global Growth Conference on Tuesday, August 11, 2009 at 3:00 p.m. (EDT) at the InterContinental Hotel in Boston, Mass.
Toggle Summary 07/31/09	AVEO's Tivozanib Demonstrates Anti-Tumor Activity in Engineered Lung Tumors Exhibiting Treatment Resistant Mutations Preclinical Data Presented at International Lung Conference; Underscores Tivozanib Potency CAMBRIDGE, Mass., July 31, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology
Toggle Summary 07/30/09	AVEO Pharmaceuticals to Present at IBC’s New Frontiers in Cancer Drug Development Conference CAMBRIDGE, Mass., July 30, 2009 – AVEO Pharmaceuticals, Inc. today announced that Murray Robinson, Ph.D., senior vice president, oncology, is scheduled to present at IBC’s New Frontiers in Cancer Drug Development Conference on Tuesday, August 4, 2009 at 1:40 p.m.
Toggle Summary 07/21/09	OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration MELVILLE, NY and CAMBRIDGE, Mass., July 21, 2009 – OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) and AVEO Pharmaceuticals, Inc. today announced that they have expanded the drug discovery and translational research collaboration announced in October of 2007.
Toggle Summary 07/08/09	AVEO Pharmaceuticals Granted Patent for Protection of its Directed Complementation Technology Novel Technology Allows Rapid Production of Genetically Defined In Vivo Tumor Models CAMBRIDGE, Mass., July 8, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies,
Toggle Summary 06/17/09	AVEO Pharmaceuticals Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition - Discovery of HeyL Gene Expression as Biomarker Marks Critical Step in Developing Targeted Therapeutics to Inhibit Notch Pathway - CAMBRIDGE, Mass., June 17, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop
Toggle Summary 06/05/09	AVEO Pharmaceuticals to Present at the 8th Annual Needham & Company Life Sciences Conference CAMBRIDGE, Mass., June 5, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the 8th Annual Needham & Company Life Sciences Conference on Thursday, June 11, 2009 at 9:00 a.m. (EDT) at the New York Palace Hotel in New York
Toggle Summary 05/29/09	AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer; Phase 2 Data Presented at ASCO Results Show Median Progression-Free Survival of 11.8 Months; Tivozanib Designated as Generic Name for AV-951 CAMBRIDGE, Mass., May 29, 2009> – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize
Toggle Summary 05/18/09	AVEO Pharmaceuticals to Present at Several Key Upcoming Medical and Industry Conferences Progression-free Survival Data from AV-951 Phase 2 Trial in Advanced Kidney Cancer to be Highlighted at ASCO CAMBRIDGE, Mass., May 18, 2009– AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted
Toggle Summary 05/13/09	AVEO Pharmaceuticals’ Scientific Advisory Board Members Recognized for Contributions to Cancer Research and Medicine SAB Members Elected to NAS and IOM; Honored with Awards from AACR and NFCR CAMBRIDGE, Mass., May 13, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today
Toggle Summary 04/21/09	AVEO Announces Positive Finding for Triple VEGF Receptor Inhibitor AV-951 Data Presented at AACR Annual Meeting; Suggests Additional Therapeutic Potential for AV-951 DENVER, Col., April 21, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology
Toggle Summary 04/19/09	AVEO Presents Novel HGF Model and Promising Preclinical Activity to Support Lead Antibody Agent SCH 900105 (AV-299) FGFR-2 Target Identification and Response Data Also Highlighted; Data Presented at AACR Annual Meeting DENVER, Col, April 19, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology
Toggle Summary 04/09/09	Data on AVEO Pharmaceuticals’ AV-951 in Liver Cancer Model and Preclinical Activity in SCH 900105 (AV-299) to be Presented at AACR 100th Annual Meeting CAMBRIDGE, Mass., April 9, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it will present during two educational sessions, nine poster
Toggle Summary 04/06/09	Breakthrough Preclinical Model for Human Cancer May Dramatically Improve Development of Effective Oncology Drugs; Data Published in PNAS AVEO Scientists Generate Human Tumors in Mice from Primary Human Breast Tissue; Provides More Realistic Genetic Context in which to Evaluate New Anti-tumor Therapies CAMBRIDGE, Mass., April 6, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in
Toggle Summary 03/26/09	AVEO Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference CAMBRIDGE, Mass., March 26, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Future Leaders in the Biotech Industry Conference on Thursday, April 2, 2009 at 1:30 p.m. (EDT) at the Millennium Broadway Hotel & Conference
Toggle Summary 03/24/09	AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies Biogen Idec to Obtain Option to Commercialize ErbB3 Antibodies Outside of North America CAMBRIDGE, Mass., March 24, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology
Toggle Summary 03/23/09	AVEO Pharmaceuticals Selected to Present at InsideVenture’s Debut Investor Conference Cambridge, Mass., March 23, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that Tuan Ha-Ngoc, president and chief executive officer, will present
Toggle Summary 03/23/09	AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies Biogen Idec to Obtain Option to Commercialize ErbB3 Antibodies Outside of North America CAMBRIDGE, Mass., March 24, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology
Toggle Summary 03/11/09	AVEO Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference CAMBRIDGE, Mass., March 11, 2009 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 9:30 a.m.
Toggle Summary 03/10/09	AVEO Initiates Phase 1b/2a Clinical Trial of Novel, Triple VEGF Receptor Inhibitor CAMBRIDGE, Mass., March 10, 2009 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the initiation of a Phase 1b/2a clinical trial of AV-951 as monotherapy
Toggle Summary 03/06/09	AVEO Pharmaceuticals to Present at the Barclays Global Healthcare Conference CAMBRIDGE, Mass., March 6, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Barclays Global Healthcare Conference on Tuesday, March 10, 2009 at 4:15 p.m. (EDT) at the Loews Miami Beach Hotel in Miami, FL.
Toggle Summary 02/25/09	AVEO Pharmaceuticals’ Oral, Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patients with Advanced Kidney Cancer 272-Patient Phase 2 Data Show 91.7 Percent Disease Control Rate and Favorable Tolerability; Interim Results Being Presented at ASCO GU Indicate Highly Differentiated VEGFR Profile CAMBRIDGE, Mass., February 25, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough
Toggle Summary 02/19/09	AVEO Initiates Phase 1b/2a Combination Trial of Novel, Triple VEGF Receptor Inhibitor CAMBRIDGE, Mass., February 19, 2009 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the initiation of a Phase 1b/2a clinical trial in breast cancer,
Toggle Summary 02/12/09	AVEO Pharmaceuticals to Present at Massachusetts Biotechnology Council CAMBRIDGE, Mass., February 12, 2009 – AVEO Pharmaceuticals, Inc. today announced that M. Isabel Chiu, Ph.D., vice president, translational research, will lead a session for the Mass Biotechnology Council’s (MBC) Drug Discovery Committee on Thursday, February 19, 2009 at 8:00 a.m.
Toggle Summary 02/11/09	AVEO Pharmaceuticals Announces Oral Presentation of Data from AV-951 Phase 2 Clinical Trial at the 2009 Genitourinary Symposium CAMBRIDGE, Mass., February 11, 2009 – AVEO Pharmaceuticals, Inc. today announced that interim safety and efficacy results from the Phase 2 clinical trial of its lead product AV-951 – a novel, highly potent and selective triple VEGF receptor inhibitor – will be presented during an oral abstract
Toggle Summary 01/06/09	AVEO Pharmaceuticals to Present at 27th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., January 6, 2009– AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 11:30 a.m. PST at the Westin St.
Toggle Summary 11/12/08	AVEO Pharmaceuticals to Present at the Lazard Capital Markets Fifth Annual Healthcare Conference CAMBRIDGE, Mass., November 12, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Lazard Capital Markets Fifth Annual Healthcare Conference on Wednesday, November 19, 2008 at 11:30 a.m. (ET) at the St.
Toggle Summary 10/20/08	AVEO Pharmaceuticals to Present at First Annual Boston Biotech R&D Conference CAMBRIDGE, MA [October 20, 2008] – AVEO Pharmaceuticals today announced that Murray O. Robinson, Ph.D., senior vice president of oncology, will present at the 2008 Boston Biotech R&D Conference on Wednesday, October 22, 2008, 2:20 p.m. (ET) at Harvard Medical School.
Toggle Summary 09/30/08	AVEO Pharmaceuticals to Present at the Third Annual JMP Securities Healthcare Focus Conference CAMBRIDGE, Mass., September 30, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Third Annual JMP Securities Healthcare Focus Conference on Tuesday, October 7, 2008 at 3:00 p.m.
Toggle Summary 09/23/08	AVEO Pharmaceuticals Initiates First Clinical Trial of Novel HGF Antagonist in Patients with Advanced Solid Tumors and Lymphomas -- SCH900105 (AV-299) Marks First of Several Monoclonal Antibodies from AVEO’s Discovery Platform; Trial Triggers Milestone Under Agreement with Schering Plough -- CAMBRIDGE, Mass., September 23, 2008 – AVEO Pharmaceuticals, Inc., today announced that it has initiated a Phase 1 clinical trial
Toggle Summary 08/25/08	AVEO Initiates Phase 1b Combination Trial of AV-951 with FOLFOX6 in Patients with Advanced Colorectal and Other Gastrointestinal Cancers CAMBRIDGE, Mass., August 25, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it has initiated another Phase 1b clinical study for its lead
Toggle Summary 07/22/08	Dyax Corp. and AVEO Pharmaceuticals Announce Antibody Library License Agreement Cambridge, MA, July 22, 2008 – Dyax Corp. (NASDAQ: DYAX) and AVEO Pharmaceuticals, Inc. announced today that Dyax has granted AVEO a non-exclusive license to Dyax’s proprietary antibody phage display libraries for the discovery and development of therapeutic antibodies. Dyax’s human antibody
Toggle Summary 05/29/08	AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients with Metastatic Renal Cell Carcinoma CAMBRIDGE, Mass., May 29, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that they have completed enrollment in their 200-patient Phase 2 clinical
Toggle Summary 05/22/08	AVEO Pharmaceuticals Granted Patent for Unique Genetic Screen to Identify Novel Cancer Drug Targets - Novel Technology Has Identified Multiple Targets Yielding Rich Pipeline of High-Value Oncology Antibodies - CAMBRIDGE, Mass., May 22, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted
Toggle Summary 05/15/08	AVEO Pharmaceuticals to Present at the 2008 Citi Investment Research Global Health Care Conference CAMBRIDGE, MA, May 15, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 2008 Citi Investment Research Global Health Care Conference on Thursday, May 22, 2008 at 11:00 a.m.
Toggle Summary 05/02/08	AVEO Pharmaceuticals to Participate in Leerink Swann Solid Tumors Roundtable Conference CAMBRIDGE, MA, May 2, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Leerink Swann Solid Tumors Roundtable Conference on Friday, May 9, 2008 at 10:20 a.m. (ET) at the Grand Hyatt in New York City.
Toggle Summary 04/14/08	AVEO Pharmaceuticals’ Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal Cancer; Clinical Activity and Tolerability in other Solid Tumors including Colon and Lung Cancers Proprietary Human Response Platform Data Reveal Distinct Biomarkers Potentially Critical to Determining Treatment Success SAN DIEGO, Calif and CAMBRIDGE, Mass, April 14, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer
Toggle Summary 04/08/08	New Clinical Data on AVEO Pharmaceuticals’ Investigational Triple VEGFR Small Molecule Inhibitor AV-951 to be Presented at AACR Annual Meeting Six Abstracts on AVEO’s Proprietary Human Response Platform Also to be Presented CAMBRIDGE, Mass., April 8, 2008 -- AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today
Toggle Summary 03/20/08	AVEO Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference CAMBRIDGE, MA, March 20, 2008 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Future Leaders in the Biotech Industry Conference on Thursday, March 27, 2008 at 2:00 p.m. (ET) at the Millennium Broadway Hotel in New York City.
Toggle Summary 03/12/08	AVEO Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference CAMBRIDGE, MA, March 12, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Cowen and Company 28th Annual Health Care Conference on Wednesday, March 19, 2008 at 4:00 p.m.
Toggle Summary 02/05/08	AVEO Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference CAMBRIDGE, MA, February 5, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 10th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 1:15 p.m.
Toggle Summary 01/31/08	AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma CAMBRIDGE, MA, January 31, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it has initiated a Phase 1b clinical trial for its lead product
Toggle Summary 01/30/08	AVEO Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference CAMBRIDGE, MA, January 30, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Merrill Lynch Nineteenth Annual Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, February 6, 2008 at
Toggle Summary 01/03/08	AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors CAMBRIDGE, MA, January 3, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of Kenneth M.
Toggle Summary 01/02/08	AVEO Pharmaceuticals to Present at 26th Annual JPMorgan Healthcare Conference CAMBRIDGE, MA, January 2, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals, is scheduled to present at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January 8, 2008 at 2:30 p.m. PT at the Westin St.
Toggle Summary 12/04/07	AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project - Agreement Highlights Growing Interest in Novel Biology Platform that Identifies Clinical Response of Cancer Drugs- CAMBRIDGE, MA, December 4, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize
Toggle Summary 11/20/07	AVEO Pharmaceuticals to Present at Lazard Capital Markets 4th Annual Healthcare Conference CAMBRIDGE, MA, November 20, 2007 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals, is scheduled to present at the Lazard Capital Markets 4th Annual Healthcare Conference on Tuesday, November 27, 2007 at 9:30 a.m.
Toggle Summary 11/13/07	Preclinical Data Published in Cancer Science Show AVEO's Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers AV-412 Has Potential to Address Drug Resistance in Non-Small Cell Lung and Breast Cancer CAMBRIDGE, MA, November 13, 2007 – AVEO Pharmaceuticals, Inc., today announced encouraging preclinical data that show the potential of AV-412, a novel next generation oral tyrosine kinase inhibitor, as a
Toggle Summary 11/06/07	Results from Phase 1 Study of AVEO’s Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease Company Initiates Phase 2 Clinical Trial of AV-951 in Patients with RCC Cambridge, MA, November 6, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced
Toggle Summary 10/30/07	AVEO Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference CAMBRIDGE, MA, October 30, 2007 – AVEO Pharmaceuticals, Inc., today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals is scheduled to present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, 2007 at 9:50 a.m.
Toggle Summary 10/30/07	AVEO Pharmaceuticals Appoints David Johnston as CFO CAMBRIDGE, MA, November 1, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of David Johnston to the newly created position of Chief
Toggle Summary 10/02/07	AVEO Pharmaceuticals to Utilize Peptech’s Breakthrough Technology to “Humanise” Internal Drug Candidates October 2, 2007, Sydney, Australia and Cambridge, MA – Peptech Limited (ASX: PTD) and AVEO Pharmaceuticals Inc. today announced they have entered into a non-exclusive research and commercialisation agreement in which AVEO will access Peptech’s SuperhumanisationTM technology to humanise
Toggle Summary 08/09/07	AVEO Announces Successful Completion of Discovery Agreement for Novel Cancer Drugs CAMBRIDGE, MA, August 9, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, announced it has successfully completed its multi-year collaborative agreement with Merck
Toggle Summary 06/18/07	AVEO Pharmaceuticals CEO Tuan Ha-Ngoc Receives Ernst & Young New England Entrepreneur of the Year Award CAMBRIDGE, MA, June 18, 2007– AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that its president and chief executive officer, Tuan Ha-Ngoc, has been awarded
Toggle Summary 05/03/07	AVEO Pharmaceuticals Closes $53 Million in Series D Funding Cambridge, MA – May 3, 2007 – AVEO Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, today announced that it has closed a $53 million Series D financing. Proceeds from this financing will be used to accelerate the
Toggle Summary 04/18/07	Novel Human Tissue Transgenic Cancer Model May Offer Significant Advance Toward Accurately Modeling Human Cancer - AVEO Pharmaceuticals Success with Breast Cancer Mouse Model Presented Today at AACR - LOS ANGELES CAMBRIDGE, Mass.--April 18, 2007--AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, presented today findings from
Toggle Summary 04/17/07	AVEO Presents Preclinical Efficacy Data on AV-412, A Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-resistant Lung Cancer Data Presented at the American Association for Cancer Research (AACR) Annual Meeting LOS ANGELES, CA, and CAMBRIDGE, MA, April 17, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, today announced encouraging
Toggle Summary 04/12/07	AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to be featured at AACR - Data to be Featured in Five Oral Presentations and Seven Poster Sessions - CAMBRIDGE, MA April 12, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, announced today that it will present a total of 12 oral
Toggle Summary 04/04/07	AVEO enters into Worldwide License and Development Agreement with Schering-Plough for AV-299, AVEO's Novel Anti-HGF Antibody - Company to Participate in Development and Commercialization - CAMBRIDGE, MA April 4, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, today announced it has entered into an exclusive worldwide agreement with
Toggle Summary 01/04/07	AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin AVEO adds Phase II-ready VEGF receptor inhibitor to growing product portfolio CAMBRIDGE, Mass. Jan. 04, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, today announced it has acquired from Kirin Brewery Co., Ltd.
Toggle Summary 10/23/06	AVEO Pharmaceuticals initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors CAMBRIDGE, MA October 23, 2006 – AVEO Pharmaceuticals, Inc. (AVEO), a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that it has begun enrolling patients in a Phase I clinical study for AV-412, a next generation oral tyrosine kinase
Toggle Summary 09/28/06	AVEO and XOMA Enter Into Supply Agreement for AVEO’s Novel Anti-HGF Antibody - Contract Follows Successful Human Engineering™ of AV-299 - Berkeley, CA and Cambridge, MA -- September 28th, 2006 – Xoma Ltd. (Nasdaq: XOMA) and AVEO Pharmaceuticals, Inc. (AVEO) today announced a $6 million agreement for XOMA to manufacture and supply AV-299, AVEO’s novel anti-HGF
Toggle Summary 09/27/06	AVEO Pharmaceuticals selected to receive 'Pharmaceutical Industry Standard of Excellence' WebAward by Web Marketing Association CAMBRIDGE, MA (September 27, 2006) - The Web Marketing Association ("WMA") today announced that it has awarded its "Pharmaceutical Industry Standard of Excellence" WebAward for 2006 to AVEO Pharmaceuticals - a biopharmaceutical company focused on the discovery and development of novel cancer
Toggle Summary 04/27/06	XOMA and AVEO Announce Agreement to Apply Human Engineering Technology™ to AV-299, AVEO's Novel Anti-HGF Antibody - Human Engineering™ Technology to Accelerate Development of Clinical Candidate - Berkeley, CA and Cambridge, MA -- April 27, 2006 -- XOMA Ltd. (Nasdaq: XOMA) and AVEO Pharmaceuticals, Inc. (AVEO) today announced an agreement for XOMA to utilize its Human Engineering™ (HE™) technology to
Toggle Summary 04/05/06	AVEO Pharmaceuticals Presents a Novel System for the Generation of Fully Human Breast Tumors in Mice at AACR 2006 - Human-in-Mouse (HIM) system represents breakthrough in modeling of human breast cancer - - HIM system offers potential for significantly improved predictability in preclinical drug testing - CAMBRIDGE, MA April 4, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company
Toggle Summary 04/04/06	AV-412 Preclinical Efficacy Data Presented at AACR 2006 - AV-412, a novel EGFR/HER2 kinase inhibitor, demonstrates potent anti-tumor activity against both Tarceva® and Iressa®-sensitive and resistant tumors - - AV-412 holds promise as a broader-acting EFGR/HER2 inhibitor - CAMBRIDGE, MA April 4, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical
Toggle Summary 03/30/06	AVEO Pharmaceuticals Appoints John Ryan, Ph.D., M.D., As Chief Medical Officer - Dr. Ryan's Expertise in Translational Medicine a Key Addition as AVEO Moves its Portfolio of Novel Cancer Medicines Forward into the Clinic - CAMBRIDGE, MA March 30, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer
Toggle Summary 03/30/06	Hercules Provides $15.0M Financing to AVEO Pharmaceuticals, Inc., a Biopharmaceutical Company Focused on the Discovery and Development of Novel Cancer Medicines Palo Alto, Calif. – March 30, 2006 – Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), a leading debt and equity growth capital provider to technology and life science companies, announced on March 29, 2006 it provided $15.0 million of debt financing to AVEO Pharmaceuticals, Inc., a
Toggle Summary 01/05/06	AVEO Pharmaceuticals acquires rights to novel anti-cancer compound from Mitsubishi Pharma Corporation AVEO's Human Response Prediction Platform to Guide Clinical Development of Multiple Kinase Inhibitor CAMBRIDGE, MA January 5, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that AVEO has

Press Releases

Press Releases

Keyword Search